<DOC>
	<DOCNO>NCT01197417</DOCNO>
	<brief_summary>The purpose study determine safety efficacy intravenous magnesium shorten duration pain crisis determine health-related quality life short term outcomes child treat intravenous magnesium acute pain crisis .</brief_summary>
	<brief_title>Intravenous Magnesium Sickle Cell Vasoocclusive Crisis</brief_title>
	<detailed_description>It well know child sickle cell disease risk acute pain crisis . The usual treatment pain crisis , intravenous fluid pain medicine morphine , change little past three decade . In pilot study , addition intravenous magnesium standard therapy decrease length stay ; however , study randomize , blind , placebo-controlled , adequately powered ass safety . We conduct multi-center , randomize , double-blind , placebo control trial 208 child , age 4-21 year . Patients randomize receive intravenous magnesium sulfate placebo every 8 hour total 6 dos , discharge . Patients return routine clinic visit 3 month discharge baseline assessment . Patients also complete health-related quality life measure 4 timepoints throughout study .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>age 421 year , inclusive Sickle cell anemia ( Hb SS ) Sickle beta zero thalassemia disease ( Hb Sβ° ) fail intravenous opioid pain management emergency department prior decision admit patient admit inpatient unit sickle cell pain crisis patient receive 12 hour intravenous pain medication prior enrollment previous enrollment study ( one admission per child eligible ) history allergy/intolerance intravenous morphine hydromorphone know cause pain ( avascular necrosis , gall bladder disease , priapism , etc . ) patient great 10 admission pain crisis past year patient maintain daily opioids chronic transfusion chronic sickle cell pain transfusion within previous two month know kidney liver failure ( elevation liver function test warrant exclusion ) know pulmonary hypertension pregnancy diagnosis bacterial infection , fever ≥39.5°C , acute chest syndrome , hemodynamic instability sepsis current oral magnesium supplementation current enrollment another therapeutic study protocol previously diagnose clinical stroke current plan use neuromuscular blocker , nifedipine , ritodrine , terbutaline allergy magnesium sulfate discharge inpatient unit within 72 hour arrival emergency department current pain crisis</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Magnesium Sulfate</keyword>
	<keyword>Pediatric</keyword>
</DOC>